| |
|
- 2001, Principal Investigator, "A Phase II Randomized, Double- blind, Placebo-ControlJed Study of XXX-XXX, A Humanized Monoclonal Antibody that Binds to the XXX-XXX, Administered by Subcutaneous Injection to Adults with Plaque Psoriasis
- 2001, Sub-Investigator, A Phase IV, Double-Blind, Randomized, Placebo-Controlled Study of XXX @ (XXX) in the Treatment of Rheumatoid Arthritis Subjects With Comorbid Disorders
- 2001, Sub-Investigator, A Phase IV, A randomized comparator, controlled, double-blind, study of the liver safety of XXX XXX versus XXX with XXX and insulin as part of step therapy in subjects with type 2 (non-insulin dependent) diabetes.
- 2001, Sub-Investigator, A Phase II Randomized, Double-blind, Placebo-Controlled Study of XXX, A Humanized Monoclonal Antibody that Binds to the XX XXX, Administered by Intravenous Infusion to Adults with Plaque Psoriasis
- 2001, Sub-Investigator, "A Phase II, Randomized, Double Blind Parallel Group Pilot Study to Evaluate the Safety and Efficacy of XXX in Patients with Uterine Leiomyomata".
- 2001, Sub-Investigator, "A Phase II, Long Term Extension Safety Study of XXX (XX mg) Administered with XXX to Post-Menopausal Women"
- 2001, Principal Investigator, A Phase II Randomized, Double-blind, Placebo-Controlled Study of XXX, A Humanized Monoclonal Antibody that Binds to the XXX Receptor, Administered by Intravenous Infusion to Adults with Plaque Psoriasis
- 2001, Principal Investigator, Phase III Vehicle-Controlled, Double- Blind Study to Assess the Safety and Efficacy of XXX 5% Cream for the Treatment of Superficial Basal Cell Carcinoma
- 2000, Sub-investigator, Phase II1 A Comparative Study of the Safety and Efficacy of XXX, 150 mg ODD for 5 Days and XXX 250 mg X xx oD for Day 1, XXX 250mg QD for Days 2-5, for the Treatment of Subjects with Acute Bacterial Exacerbation of Chronic Bronchitis
- 2000, Sub-Investigator, A Phase III study, An open Non- Competitive Trail with XXX, XXX 300mg PO BID for Seven Days in the Treatment of Acute Bacterial Sinusitis in Conjunction with Antral Sinus Aspirations for Diagnostic Microbiology
- 2000, Principal Investigator, "A Phase III Double-Blind efficacy and Safety Study of XXX (10mg) in Addition to XXX Compared to Placebo in Subjects with Primary Hypercholesterolemia"
- 2000, Sub-Investigator, "A Phase III Double-Blind, Placebo- controlled, Randomized, Multi-center Study to Investigate the Efficacy and Safety of XXX in Non-Constipated Patients with Established Bowel Syndrome"
- 2000, Sub-Investigator, "A Phase II Pilot Study to Evaluate the Safety and Efficacy of X XXX Administered With XXX to Post- Menopausal Women"
- 2000 Principal Investigator, Phase IV Open Label Pilot Study of XXX ( XXX) 5% Cream for the Treatment of Warts ( Common and Flat Warts) in Children and Adults
- 2000, Principal Investigator," A Phase III Randomized, Double- Blind, Placebo-Controlled, Dose-Comparison Study to Evaluate the Efficacy and Safety of Intramuscular Administration of XXX (XXX, XXX XXX XXX) in Subjects with Chronic Plaque Psoriasis"
- 2000, Principal Investigator, "A Phase II Two-Part, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Multiple dose Clinical Trial of XXX-XXX in Patients with Moderate to Severe Plaque Psoriasis
|